Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230516 · ClinicalTrials.gov registry record · Phase 4
Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00230516 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 100 participants.
The verdict
NCT00230516, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®
Interventions
- DRUG Nexium
- DRUG Prevacid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230516
The ClinicalTrials.gov registry entry for NCT00230516 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nexium is the first listed.
NCT00230516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230516 about?
NCT00230516 is a clinical study titled "Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects". This study is intended to evaluate whether intravenous (iv) esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®
What is the current status of trial NCT00230516?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2005-09. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00230516?
The interventions under investigation include: Nexium (DRUG), Prevacid (DRUG).
Who is sponsoring clinical trial NCT00230516?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.